Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
To compare the efficacy in terms of the pathological complete response rate (pCR) to
preoperative administration of qw or q3w Paclitaxel, Carboplatin and Trastuzumab (PCH)